Reported about 22 hours ago
Sarepta Therapeutics has declined the FDA's request to halt Elevidys shipments following three associated deaths, including two teenage boys with Duchenne muscular dystrophy. Despite the FDA's concerns over safety, Sarepta maintains that data shows no new safety issues for patients who can walk. The company's stock plummeted 36%, raising doubts about the future of Elevidys, a critical part of its product revenue. Analysts express concern about the increasing risks of market removal amidst ongoing investigations into the drug's safety.
Source: YAHOO